cNP8
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout cNP8
cNP8 is a phase 1 stage product being developed by United Therapeutics for Burns. The current trial status is completed. This product is registered under clinical trial identifier NCT06223009. Target conditions include Burns.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06223009 | Phase 1 | Completed |
Competing Products
12 competing products in Burns
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| R-Pdf/Gbb 0.01% gel | Johnson & Johnson | Phase 2 | 52 |
| Ceftolozane/tazobactam | Merck | Approved | 85 |
| linezolid | Pfizer | Phase 1 | 32 |
| Somatropin + 0.09% Saline Solution | Pfizer | Phase 2/3 | 64 |
| Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867) | Bayer | Phase 3 | 74 |
| cP12 | United Therapeutics | Phase 2 | 49 |
| Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal Medications | Viatris | Approved | 82 |
| Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin | Baxter | Phase 1/2 | 38 |
| I-020502 | Baxter | Phase 2 | 49 |
| Pathogen-Reduced Plasma + Crystalloid Solutions | Cerus | Approved | 77 |
| NexoBrid + Gel Vehicle | MediWound | Phase 3 | 69 |
| NexoBrid | MediWound | Phase 3 | 69 |